STAT+: Pharmalittle: Amgen pricing for Humira biosimilar may not help patients; pharma wins court battle over drug discount program

Amgen’s long-awaited pricing for its Humira biosimilar suggests the biggest winners may be health insurers and others in the supply chain, but not patients.